



Patent Application  
Attorney Docket No. PC25291A

I hereby certify that this correspondence is being deposited with the United States Postal Service as First-Class Mail in an envelope addressed to: Hon. Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450 on this 18th day of February, 2004.

By

*Irene Grantham*  
(Signature of person mailing)  
Irene Grantham

(Typed or printed name of person)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Michael J. Munchhof, et al. :

APPLICATION NO.: 10/666,192

: Examiner:

FILING DATE: September 17, 2003

: Group Art Unit: 1645

TITLE: NOVEL IMIDAZOLE COMPOUNDS AS :  
TRANSFORMING GROWTH FACTOR (TGF)  
INHIBITORS

Hon. Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

Sir:

SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT  
UNDER 37 CFR 1.97(b)

Applicant(s) herein make(s) available to the U.S. Patent and Trademark Office a copy of PTO-FB-A820 which lists the references cited by Applicants, copies of which are enclosed.

The Examiner is requested to consider carefully the complete text of these references in connection with the examination of the above-identified application in accord with 37 C.F.R. § 1.104(a).

It is requested that the references listed on the attached form PTO-FB-A820 be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. § 1302.12).

A prompt and favorable response is earnestly solicited.

Date:

*02/18/04*

Respectfully submitted,

*Christine S. Lee*

Christine S. Lee  
Attorney for Applicant(s)  
Reg. No. 42,788

Pfizer Inc.  
Patent Department, MS 8260-1611  
Eastern Point Road  
Groton, Connecticut 06340  
(860) 686-2144

